Preiß, Jan C. http://orcid.org/0000-0002-0901-1422
Schneidereit, Oliver
Siegmund, Britta
Hoffmann, Jörg C.
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01 GI 0486)
Article History
Accepted: 15 May 2019
First Online: 24 May 2019
Compliance with ethical standards
:
: J.C.P. served as a consultant for MSD, Pfizer, Takeda, and Biogen and received lecture fees from Vifor, Falk, Janssen, Abbvie, Pfizer, Vifor, MSD, and Takeda. B.S. received a research grant from Pfizer, served as consultant for Falk, Janssen, MSD, Abbvie, Celgene, Lilly, Takeda, Pfizer, and Hospira and received lecture fees from Abbvie, Celgene, Falk, Ferring, Janssen, MSD, Merck, and Takeda; all funds were transferred to the Charité - Universitätsmedizin Berlin, Germany. J.C.H. served as consultant for Amgen, Astra, Falk, Hexal, Janssen, Pfizer, Steigerwald, and Takeda, and received lecture fees from Falk, Janssen, MSD, Pfizer, and Takeda.
: All procedures performed in this study were in accordance with ethical standards of the institutional research committee (approval number EA4/092/09) and with the 1964 Helsinki declaration and its later amendments. All patient-related data were anonymized after open questions had been resolved in responders who provided contact information. The local data protection commissioner approved the study protocol.
: Informed consent was assumed if patients sent in their questionnaire.